KLRA
Kailera Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Ronald C. Renaud Jr.
IPO Date
2026-04-17
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Kailera Therapeutics, Inc.
CEO
Ronald C. Renaud Jr.
IPO Date
2026-04-17
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 0 |
| $0.00 |
| 11 Jun 2026 | Renaud Ronald C JR | director, officer: CEO & President | M-Exempt | Acquired | 38,094 | $5.25 |
| 11 Jun 2026 | Renaud Ronald C JR | director, officer: CEO & President | M-Exempt | Disposed | 38,094 | $5.25 |
| 22 Apr 2026 | RTW INVESTMENTS, LP | 10 percent owner | C-Conversion | Acquired | 10,276,820 | $0.00 |
| 22 Apr 2026 | RTW INVESTMENTS, LP | 10 percent owner | P-Purchase | Acquired | 500,000 | $16.00 |
| 22 Apr 2026 | RTW INVESTMENTS, LP | 10 percent owner | C-Conversion | Disposed | 8,250,000 | $0.00 |
| 22 Apr 2026 | RTW INVESTMENTS, LP | 10 percent owner | C-Conversion | Disposed | 2,026,820 | $0.00 |
| 22 Apr 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | C-Conversion | Acquired | 9,477,719 | $0.00 |
| 22 Apr 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | C-Conversion | Acquired | 2,034,133 | $0.00 |